Cambridge, MA, Rotterdam, The Netherlands, Suzhou, CN – June 11^th, 2020

Harbour BioMed (HBM) announced today the appointment of Dr. Jon Wigginton M.D., to the company’s scientific advisory board (SAB). Dr. Wigginton is a physician-scientist and leader in immuno-oncology drug development with more than 20 years in senior roles at the U.S, National Institutes of Health, Bristol-Myers Squibb, Merck, MacroGenics, and Cullinan Oncology, where he is Chief Medical Officer.  

“Dr. Wigginton is a seasoned scientific leader whose expertise spans basic scientific research, translational medicine and clinical development,” said Dr. Jingsong Wang, M.D., Ph,D., Founder, Chairman and CEO of Harbour BioMed. “We are very excited to have Dr. Wigginton join our SAB team and look forward to his guidance in accelerating our programs to develop the next generation of immuno-oncology therapeutics.”

"HBM has an exciting portfolio and its research stands at the cutting edge of scientific progress that is being conducted to bring next generation immuno-therapeutics  to address unmet medical needs." said Dr. Wigginton: "I look forward to working with Jingsong and his team.”

Dr. Wigginton recently joined Cullinan Oncology, where he serves as Chief Medical Officer, and leads clinical development for Cullinan’s portfolio companies. He also serves as an Advisor at MPM Capital, where he provides input on potential oncology investments and clinical development plans for portfolio companies. Previously, Dr. Wigginton served as Chief Medical Officer and Senior Vice-President, Clinical Development at MacroGenics. 

Previously, Dr. Wigginton served as Therapeutic Area Head, Immuno-Oncology Early Clinical Research at Bristol-Myers Squibb. At BMS, he oversaw the early clinical development of the Company’s Immuno-Oncology portfolio, from first-in-man through proof-of-concept, co-led the BMS International Immuno-Oncology Network, and served in a governance role for immuno-oncology discovery. These efforts led to demonstration of proof-of-concept for both anti-PD-1 and anti-PD-L1 antibodies in patients with a range of different cancers, and for the anti-PD-1/anti-CTLA-4 combination in melanoma.

Dr. Wigginton also had a lengthy career at the National Cancer Institute, serving as Head of the Investigational Biologics Section in the Center for Cancer Research, where he led an integrated basic, translational, and clinical research effort focused on combination immunotherapy. Dr. Wigginton’s work has been recognized through numerous peer-reviewed publications, abstracts, and invited presentations at various national and international scientific programs, and he previously served as President of the Society for Immunotherapy of Cancer (SITC).

About Harbour BioMed

 
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

 
The Company’s proprietary antibody technology platforms Harbour Mice^® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice^® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.  

For further information, please refer to www.harbourbiomed.com

Contact：

Atul Deshpande PhD, MBA

Chief Strategy Officer and Head, US Ops.

Harbour BioMed

Phone: +1-908-210-3347

E-mail: atul.deshpande@harbourbiomed.com